GSK publishes Q3 2026 results infographic
Bitget2026/10/28 07:20- GSK reported Q3 2026 sales of £8.9 billion, up 5%; core operating profit rose 5% to £3.1 billion.
- Specialty Medicines sales increased 15% to £3.9 billion; vaccine sales fell 2% to £2.6 billion.
- General Medicines sales held steady at £2.4 billion; total earnings per share fell 21% to 38.5p.
- Core earnings per share rose 1% to 54.6p; the dividend was 17p per share.
- Hibsago secured US and Japanese approvals; US regulators also cleared Jemperli for rectal cancer and Jideytro for lung cancer.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Silver Price Forecast: XAG/USD trades flat around $53 ahead of US inflation data
Swiss Franc holds ground as US Dollar consolidates ahead of CPI inflation data
Net profit surges fivefold but masks decline in core business; crypto mining companies' shift to AI poses hidden risks
Marathon Holdings' Q3 net profit reached $632 million, up 413% year-on-year. However, its mining revenue declined by 35%. The company relied on selling 13,500 BTC to pay off debts and is now betting on AI infrastructure, increasing the risk of an imbalanced profit structure.
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Crypto prices
More
